RankingsPricing
  1. US-listed companies
  2. ALNYLAM PHARMACEUTICALS, INC.
  3. Financials
  4. Operating income

ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap
$56.9B
P/E ratio
SummaryFinancials
Period EndOperating income (Million USD)YoY (%)
Dec 31, 2024-177-37.31%
Dec 31, 2023-282-64.06%
Dec 31, 2022-785+10.78%
Dec 31, 2021-709-14.46%
Dec 31, 2020-828-11.81%
Dec 31, 2019-939+15.31%
Dec 31, 2018-815+62.91%
Dec 31, 2017-500+17.78%
Dec 31, 2016-425+43.44%
Dec 31, 2015-296-26.91%
Dec 31, 2014-405+335.73%
Dec 31, 2013-93-28.21%
Dec 31, 2012-129+136.16%
Dec 31, 2011-55+24.39%
Dec 31, 2010-44

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)